

Sema3A median Fluoresence Intensity
8
7
6
5
4
3
2
1
0
**
0
0.1
TGFβ1 (ng/mL)

FIG. 1



LS Mean VAS Change from Baseline
0.00
-5.00
-10.00
-15.00
-20.00
-25.00
-30.00
-35.00
-40.00
-45.00
0
6
12
18
24
30
36
Minimally important change
#, §
*, ϕ
*, ϕ
ϕ
Saline
HA
6 million MPCs
18 million MPCs
P ≤ 0.05 in the following instances
* MPC 6M vs. Saline
ϕ MPC 18M vs. Saline
MPC 6M vs. HA
§ MPC 18M vs. HA

FIG. 2



6M MPCs
VAS at Baseline and 24 Months[1]
24 Month Median 37.0
Baseline Median 71.5
% Patients
Baseline VAS
24 Months VAS
Not a normal distribution of results as would be seen with an analgesic medication
Saline
VAS at Baseline and 24 Months[1]
Baseline Median 66.0
24 Month Median 66.5
% Patients
Baseline VAS
24 Months VAS
Relatively normal distribution of results similar to an analgesic medication

FIG. 3



% Patients With Reduced Pain Response Levels at 12 Months
VAS Responder Rates by Response Thresholds at 12 months
MIC[1]
Market & Payer Expectation[2]
Proportion of Subjects
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
VAS % improvement From Baseline
Saline
HA
6 million MPCs
18 million MPCs

FIG. 4



6 & 12 Months
50% Reduction in VAS LBP with No Intervention[1]
% Responder Rate
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
* #
56.7%
43.3%
15.0%
15.0%
Saline (n=20)
HA (n=20)
6-million MPCs (n=30)
18-million MPCs (n=30)
12 & 24 Months
50% Reduction in VAS LBP with No Intervention[1]
% Responder Rate
*
46.7%
30.0%
20.0%
10.0%
Saline (n=20)
HA (n=20)
6-million MPCs (n=30)
18-million MPCs (n=30)2

FIG. 5



Mean VAS Improvement (pts) from Baseline
45
40
35
30
25
20
15
10
5
0
Minimally Important Change*
38.3
12.4
10.1
8
35.7
11.9
8.1
33.6
30.9
Short-Term ≤ 3 Months
Intermed.-Term >3 to 12 Months
Long-Term ≥12 to <24 Months
Long-Term ≥24 Months
6-million MPCs**
NSAID***
Opioid*
Opioid+NSAID*
Multi. Opioids*

FIG. 6



LS Mean ODI Change from Baseline
0.00
-5.00
-10.00
-15.00
-20.00
-25.00
-30.00
0
6
12
18
24
30
36
Minimally Important Change
FDA Functional Improvement Threshold
Saline
HA
6 million MPCs
18 million MPCs

FIG. 7



Proportion of Subjects
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
5
10
15
20
25
30
ODI Point Improvement From Baseline
MIC[1]
FDA Expectation[2]
Saline
HA
6 million MPCs
18 million MPCs

FIG. 8



6 & 12 Months
15 Point Reduction in ODI with No Intervention[1]
% Responder Rate
50.0%
45.0%
40.0%
35.0%
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
*
ϕ
46.7%
46.7%
30.0%
15.0%
Saline (n=20)
HA (n=20)
6-million MPCs (n=30)
18-million MPCs (n=30)
12 & 24 Months
15 Point Reduction in ODI with No Intervention[1]
% Responder Rate
*
ϕ
46.7%
43.3%
25.0%
10.0%
Saline (n=20)
HA (n=20)
6-million MPCs (n=30)
18-million MPCs (n=30)
P ≤ 0.05 in the following instances
* MPC 6M vs. Saline
ϕ MPC 18M vs. Saline
MPC 6M vs. HA
§ MPC 18M vs. HA

FIG. 9



Mean ODI Improvement (pts) from Baseline
25
20
15
10
5
0
FDA Functional Improvement Threshold
Minimally Important Change*
18.4
8
6.3
6.2
18.2
19.9
3.7
18.9
Short-Term ≤ 3 Months
Intermed.-Term >3 to 12 Months
Long-Term ≥12 to <24 Months
Long-Term ≥24 Months
6M MPCs**
NSAID***
Opioid*
Opioid+NSAID*
Multi. Opioids*

FIG. 10



% Responder Rate
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
1 Month
3 Months
6 Months
12 Months
24 Months
36 Months
25.0%
33.3%
25.0%
30.0%
20.0%
20.0%
33.3%
36.7%
25.0%
30.0%
56.7%*
43.3%
15.0%
25.0%
46.7%*
40.0%
15.0%
25.0%
40.0%
33.3%
15.0%
25.0%
40.0%
33.3%
Saline (n=20)
HA (n=20)
6-million MPCs (n=30)
18-million MPCs (n=20)
P ≤ 0.05 in the following instances
* MPC 6M vs. Saline
ϕ MPC 18M vs. Saline
MPC 6M vs. HA
§ MPC 18M vs. HA

FIG. 11



Treatment Success Responders[1,2]
At 6 & 12 Months
% Responder Rate
50.0%
45.0%
40.0%
35.0%
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
*
42.3%
ϕ
36.7%
15.0%
10.0%
Saline
HA
6M MPCs
18M MPCs
Treatment Success Responders[1,2]
At 12 & 24 Months
% Responder Rate
*
36.7%
30.0%
15.0%
10.0%
Saline
HA
6M MPCs
18M MPCs
P ≤ 0.05 in the following instances
* MPC 6M vs. Saline
ϕ MPC 18M vs. Saline
MPC 6M vs. HA
§ MPC 18M vs. HA

FIG. 12